Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on renal function in patients with ST-segment elevation myocardial infarction treated with primary or rescue percutaneous coronary intervention

EuroIntervention

Volumn 5, Issue 5, 2009, Pages 604-609

  Osherov, Azriel B ^a,b   Roguin, Ariel ^a   Aronson, Doron ^a   Grenadier, Ehud ^a   Kerner, Arthur ^a   Boulus, Monther ^a   Kapeliovich, Michael ^a   Hani, Amad ^b   Hammerman, Haim ^a   Beyar, Rafael ^a   Nikolsky, Eugenia ^a  

^a Cardiology Department   (Israel)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Myocardial infarction; PCI; Therapy with platelet glycoprotein IIb IIIa receptor inhibitors (GP IIb IIIa)

Indexed keywords

ABCIXIMAB; CREATININE; EPTIFIBATIDE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; FIBRINOGEN RECEPTOR;

ADULT; ARTICLE; BLEEDING; BLOOD RHEOLOGY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FUNCTIONAL ASSESSMENT; HEMODYNAMICS; HOSPITALIZATION; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION INHIBITION; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DRUG ANTAGONISM; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART INFARCTION; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955492543     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV5I5A97     Document Type: Article

References (30)

1. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-8.
2. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375. (Pubitemid 27506242)
3. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264. (Pubitemid 34535335)
4. Haller C, Schick CS, Zorn M, Kubler W. Cytotoxicity of radiocontrast agents on polarized renal epithelial cell monolayers. Cardiovasc Res 1997;33:655-665. (Pubitemid 27092867)
5. Zhang J, Duarte CG, Ellis S. Contrast medium- and mannitolinduced apoptosis in heart and kidney of SHR rats. Toxicol Pathol 1999;27:427-435. (Pubitemid 29357621)
6. Erley CM, Heyne N, Rossmeier S, Vogel T, Risler T, Osswald H. Adenosine and extracellular volume in radiocontrast media-induced nephropathy. Kidney Int Suppl 1998;67:S192-194.
7. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int 1999;56:206-210. (Pubitemid 29300536)
8. Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992;41:1408-1415.
9. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:1451-1458.
10. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up.Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
11. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G,Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC)Investigators.Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966. (Pubitemid 34983245)
12. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26-32. (Pubitemid 36044399)
13. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003;92:651-5. (Pubitemid 37103012)
14. De Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med.1999;130:461-70.
16. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150: 1237-1242. (Pubitemid 20188457)
17. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ,Moses JW, Stone GW, Leon MB, Dangas G.A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399. (Pubitemid 39303939)
18. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108:2769-75. (Pubitemid 37498979)
19. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ,Moussa I, Stone GW, Moses JW, Leon MB, Mehran R. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-19. (Pubitemid 40051105)
20. Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:143-149. (Pubitemid 19033091)
21. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997;203:605-610. (Pubitemid 27227401)
22. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Shimshak TM, Hartzler GO. High-dose contrast agent administration during complex coronary angioplasty. Am Heart J 1990;120:533-536. (Pubitemid 20312580)
23. Albert SG, Shapiro MJ, Brown WW, Goodgold H, Zuckerman D, Durham R, Kern M, Fletcher J, Wolverson M, Plummer ES. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol 1994;29:618-623. (Pubitemid 24211183)
24. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-358. (Pubitemid 34113804)
25. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002; 55: 169-173. (Pubitemid 34127374)
26. Lancelot E, Idee JM, Couturier V, Vazin V, Corot C. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of Nephrotoxicity. J Appl Toxically 1999;19:341-346.
27. Liss P, Nygren A, Olsson U, Ulfendahl HR, Erikson U. Effects of contrast media and mannitol on renal medullary blood flow and red cell aggregation in the rat kidney. Kidney Int 1996;49:1268-1275
28. Uder M, Humke U, Pahl M, Jansen A, Utz J, Kramann B. Nonionic contrast media iohexol and iomeprol decrease renal arterial tone: comparative studies on human and porcine isolated vascular segments. Invest Radiol 2002;37:440-447.
29. Sunnegardh O, Hietala SO, Wirell S, Ekelund L. Systemic, pulmonary and renal hemodynamic effects of intravenously infused iopentol. A comparison in the pig of a new low osmolar non-ionic medium with saline and iohexol. Acta Radiol 1990;31:395-399.
30. Scheller B, Hennen B, Thünenkötter T, Mrowietz C, Markwirth T, Schieffer H, Jung F. Effect of X-ray contrast media on blood flow properties after coronary angiography. Thromb Res 1999;96:253-260.